Business - Monitor   

Ranbaxy gets FDA nod for Ganciclovir

NEW DELHI: Ranbaxy Laboratories has received the approval from the U.S. Food and drug Administration to produce and commercialize Ganciclovir capsules in 250 mg and 500 mg strength. Ganciclovir Capsules are indicated for the prevention of Cytomegalovirus(CMV) disease in solid organ transplant recipients and in individuals with advanced HIV infection at risk for developing CMV disease, according to a release.

— Our Bureau

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary |

Stories in this Section

• Overall balance shows $17b surplus in 02-03
• S&P's India outlook negative
• Intel launches new processors
• Revised norms show higher FDI inflow
• Sensex breaches 3600-mark
• Rupee tumbles 7 paise to $46.46
• IFFCO major bidder for MFL stake
• SBI concludes $100 m credit for Reliance
• NIIT to set up 15 CoEs in China
• 12 firms get nod for 'carbon trading'
• SAP to increase workforce
• Chennai Petro's expansion nearing completion
• Tata Power, PGCIL form JV for power transmission
• Chambal acquires major stake in Australian firm
• Exchange rates
• Stock Market Index
• Bullion rates
• Ranbaxy gets FDA nod for Ganciclovir
• Marginal rise in Consumer Price Index
• Tata AIG premium income trebles

Copyright © 2003, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu